| Current Price | $217.17 | Mkt Cap | $80.4B |
|---|---|---|---|
| Open | $215.84 | P/E Ratio | 23.43 |
| Prev. Close | $214.65 | Div. (Yield) | $2.14 (1.0%) |
| Daily Range | $215.53 - $217.86 | Volume | 111,957 |
| 52-Wk Range | $206.00 - $217.86 | Avg. Daily Vol. | 1,424,887 |
A medical technology company in orthopaedics products. Its products include implants, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation.
| Current Price | $217.17 | Mkt Cap | $80.4B |
|---|---|---|---|
| Open | $215.84 | P/E Ratio | 23.43 |
| Prev. Close | $214.65 | Div. (Yield) | $2.14 (1.0%) |
| Daily Range | $215.53 - $217.86 | Volume | 111,957 |
| 52-Wk Range | $206.00 - $217.86 | Avg. Daily Vol. | 1,424,887 |
The best Bull and Bear pitches based on recency and number of recommendations.
About half of Stryker's revenue comes from reconstructive orthopedic implants, where the firm is a top-tier provider of knees and hips. Demographic trends of obesity and increased life span.Stock price has gone net nowhere since 2004, as eps… More
With rising unemployment and subsequent loss of health insurance, people are putting off elective hip and knee surgery which adversely affects Stryker.Also, chief executive Stephen MacMillan recently backed off from giving any long term sales and… More
Read the most recent pitches from players about SYK.
Recs
TMFTypeoh
(93.69)
Submitted: 1/30/2019 10:21:37 AM :
Start Price:
$174.78
NYSE:SYK Score:
-1.80
steady as she goes.
Recs
rmburkettjr30
(31.08)
Submitted: 7/30/2016 9:01:16 PM :
Start Price:
$111.32
NYSE:SYK Score:
+41.28
This is one of the last few independent implant/medical device companies. They seem to be doing very well for a company that didn't have to join forces with anyone else. My guess is eventually they will be acquired by someone but until then they will continue to outperform.
Recs
TurksFan
(42.14)
Submitted: 9/29/2015 10:27:56 AM :
Start Price:
$88.98
NYSE:SYK Score:
+67.82
I decided to move off of the energy stocks this week and pick a medical device/equipment/neurovascular innovator, Stryker Corporation (NYSE: SYK). Besides being a homie (headquartered in Michigan), you will likely see it's products in any hospital you visit. Full disclosure, I own Stryker and have for years. However recently, the price declined due to Congressional rabble rousing and the fear of litigation due to implants. It's acquisition strategy has helped it keep its market share. The recent acquisition of Trausin Company maintains its foothold in the China market. Due to the recent volatility of the market, and the avoidance of anything related to China or medical technology, this pick is a let's see what happens pick.
Find the members with the highest scoring picks in SYK.
db74006 (52.44) Score: +377.25
The Score Leader is the player with the highest score across all their picks in SYK.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
|
db74006 | 52.44 | 3/23/2009 |
|
NS | $27.51 | +686.16% | +321.34% | +364.82 | 0 Comment |
| Xitopie | < 20 | 4/3/2009 |
|
5Y | $28.71 | +653.20% | +299.38% | +353.81 | 1 Comment | |
| tpulley | 42.37 | 3/23/2009 |
|
NS | $27.80 | +678.07% | +326.42% | +351.65 | 1 Comment | |
| saaf569 | 57.99 | 3/23/2009 |
|
3Y | $27.80 | +678.07% | +326.42% | +351.65 | 0 Comment | |
| Moreliator | 41.25 | 3/23/2009 |
|
3Y | $28.06 | +670.86% | +319.29% | +351.58 | 1 Comment | |
| bejeweledfool | 50.69 | 4/6/2009 |
|
5Y | $28.82 | +650.48% | +302.72% | +347.76 | 0 Comment | |
| MaxPower13 | 98.34 | 4/6/2009 |
|
5Y | $28.70 | +653.65% | +306.62% | +347.02 | 0 Comment | |
| chaddodson | 63.46 | 4/7/2009 |
|
3Y | $28.68 | +654.11% | +307.81% | +346.30 | 0 Comment | |
| MuhaPSU | 98.47 | 4/7/2009 |
|
5Y | $28.59 | +656.39% | +311.36% | +345.04 | 0 Comment | |
|
|
tacross3 | 54.08 | 4/8/2009 |
|
3Y | $28.84 | +649.79% | +309.16% | +340.64 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
